Back to Top
Maftivimab Biosimilar - Research Grade
Frequently Bought Together
Loading...
Maftivimab Biosimilar - Research Grade
Endotoxin
≤ 1.0 EU/mg as determined by the LAL method
Purity
>90% by SDS-PAGE
Species Reactivity
Human
Target
Zaire Ebola virus
Concentration
>1mg/ml
Isotype
IgG1 - kappa
Host
CHO Cells
Antibodies Against The Same Target
Sequence
https://www.imgt.org/mAb-DB/
Buffer
ICH3002
Shipping Conditions
Blue ice
Background
Antibodies directed against the Zaire ebolavirus glycoprotein are vital instruments for hemorrhagic-fever and antiviral countermeasure research. This human IgG1 (kappa) recombinant antibody is an unconjugated, non-therapeutic analog of maftivimab that binds the Zaire Ebola virus antigen and is offered strictly for research use only (RUO). It is formulated to a low-endotoxin specification compatible with in vivo experimentation and manufactured at scalable milligram-to-gram volumes to serve high-throughput and heavy-consumption laboratories. The reagent is well suited to viral neutralization assays, in vitro antigen-binding characterization, and preclinical in vivo challenge models studying protective immunity.
Purification Method
This monoclonal antibody was purified using Protein A
Formulation
Sterile, preservative-free, solution in PBS. BSA and Azide free.
Storage
This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
Applications
Functional Assays
Application Notes
This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
Use
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Delivery Time
3-4 weeks
Faq (q&a)
Q: Is the Maftivimab biosimilar available in gram quantities?
A: Yes — it is supplied in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.
Q: Is this research-grade Maftivimab biosimilar suitable for in vivo studies?
A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).
Q: What does the Maftivimab biosimilar target?
A: It is a non-therapeutic biosimilar of Maftivimab used as a binding and neutralization reagent against Zaire Ebola virus; for research use only.
Write Your Own Review
Is the Maftivimab biosimilar available in gram quantities?
Yes — it is supplied in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.
Is this research-grade Maftivimab biosimilar suitable for in vivo studies?
Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).
What does the Maftivimab biosimilar target?
It is a non-therapeutic biosimilar of Maftivimab used as a binding and neutralization reagent against Zaire Ebola virus; for research use only.
Who Viewed This Also Viewed
Add recommended extras
-
In Vivo Buffer pH7.2$112.50
